Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$127.69 USD

127.69
1,121,487

-0.12 (-0.09%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $127.70 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Philips (PHG) Aids Image-Guided Treatment With New Stent System

by Zacks Equity Research

Philips (PHG) boosts its Image-Guided Therapy portfolio with the Duo Venous Stent System, strengthening its Diagnosis & Treatment segment.

Urmimala Biswas headshot

3 PEG-Based Value Picks to Boost Your Portfolio Returns

by Urmimala Biswas

Invest in shares of Eldorado Gold (EGO), Sasol (SSL) and DaVita (DVA) that hold huge upside potential.

Zacks Equity Research

DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?

by Zacks Equity Research

DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings (ITGR) Stock

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.

Zacks Equity Research

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

by Zacks Equity Research

Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.

Zacks Equity Research

The Zacks Analyst Blog Highlights CareCloud, DaVita, RadNet, SkyWest and American Express

by Zacks Equity Research

CareCloud, DaVita, RadNet, SkyWest and American Express are included in this Analyst Blog.

Zacks Equity Research

Surmodics (SRDX) Inks Group Purchasing Agreement With Premier

by Zacks Equity Research

Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.

Tirthankar Chakraborty headshot

5 Stocks to Gain as Service Side of the Economy Bounces Back

by Tirthankar Chakraborty

With service sector activity rebounding in recent times, it's worth placing bets on stocks such as CareCloud (CCLD), DaVita (DVA), RadNet (RDNT), SkyWest (SKYW) and American Express (AXP).

Zacks Equity Research

Here's Why You Should Hold McKesson (MCK) in Your Portfolio Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

Veeva Systems' (VEEV) Vault EDC to Boost Tigermed's Workflow

by Zacks Equity Research

Veeva Systems' (VEEV) Vault EDC is likely to streamline key processes to accelerate study builds and make mid-study amendments with no downtime.

Zacks Equity Research

DaVita (DVA), Nuwellis Extend Pilot Collaboration for Aquadex

by Zacks Equity Research

DaVita (DVA) extends its pilot collaboration with Nuwellis to conduct additional testing of the Aquadex ultrafiltration treatment for adult patients suffering from congestive heart failure and related conditions.

Zacks Equity Research

Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how DaVita HealthCare (DVA) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

Zacks Equity Research

DaVita HealthCare (DVA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

The latest trading day saw DaVita HealthCare (DVA) settling at $143.18, representing a -0.46% change from its previous close.

Zacks Equity Research

Are Investors Undervaluing DaVita (DVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite

by Zacks Equity Research

BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.

Zacks Equity Research

Philips (PHG) Boosts Precision Diagnosis With AI Platform

by Zacks Equity Research

Philips (PHG) boosts its Precision Diagnosis portfolio with an AI-powered ultrasound platform, strengthening its Diagnosis & Treatment segment.

Sanghamitra Saha headshot

Play Likely Earnings Beat With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Top-ranked stocks MGM Resorts International (MGM), Burlington Stores (BURL), Sterling Infrastructure Inc (STRL), Dropbox (DBX) and DaVita (DVA) are likely to beat on the bottom line in their upcoming releases.

Zacks Equity Research

Waters (WAT) Expands Mass Spectrometer Portfolio With Xevo MRT

by Zacks Equity Research

Waters (WAT) boosts MS offerings with the launch of Xevo MRT, strengthening its Waters operating segment's portfolio.

Zacks Equity Research

Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now

by Zacks Equity Research

BD's (BDX) robust product portfolio raises optimism about the stock.

Zacks Equity Research

Patterson Companies' (PDCO) New Launch to Boost Patient Service

by Zacks Equity Research

Patterson Companies' (PDCO) Patterson CarePay+ is likely to improve overall patient care and streamline practice operations.

Zacks Equity Research

DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in kidney care.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now

by Zacks Equity Research

Revvity's (RVTY) strong product portfolio raises optimism about the stock.